Anti-EGF Receptor Aptamer-Guided Co-Delivery of Anti-Cancer siRNAs and Quantum Dots for Theranostics of Triple-Negative Breast Cancer

Theranostics
Min Woo KimYong Serk Park

Abstract

Many aptamers have been evaluated for their ability as drug delivery vehicles to target ligands, and a variety of small interfering RNAs (siRNAs) have been tested for their anti-cancer properties. However, since these two types of molecules have similar physicochemical properties, it has so far been difficult to formulate siRNA-encapsulating carriers guided by aptamers. Here, we propose aptamer-coupled lipid nanocarriers encapsulating quantum dots (QDs) and siRNAs for theragnosis of triple-negative breast cancer (TNBC). Methods: Hydrophobic QDs were effectively incorporated into lipid bilayers, and then therapeutic siRNAs were complexed with QD-lipid nanocarriers (QLs). Finally, anti-EGFR aptamer-lipid conjugates were inserted into the QLs for TNBC targeting (aptamo-QLs). TNBC-targeting aptamo-QLs were directly compared to anti-EGFR antibody-coupled immuno-QLs. The in vitro delivery of therapeutic siRNAs and QDs to target cells was assessed by flow cytometry and confocal microscopy. The in vivo targeting of siRNAs to tumors and their therapeutic efficacy were evaluated in mice carrying MDA-MB-231 tumors. Results: Both types of EGFR-targeting QLs showed enhanced delivery to target cancer cells, resulting in more effective gene s...Continue Reading

Citations

Jun 21, 2019·Journal of Nanobiotechnology·Chen ZhangLee Jia
Oct 1, 2019·Advanced Materials·Byungji KimMichael J Sailor
Jan 29, 2020·Nucleic Acid Therapeutics·Elena ZavyalovaAlexey Kopylov
Mar 4, 2020·Expert Opinion on Biological Therapy·Vivian Weiwen XueWilliam Chi Shing Cho
Oct 23, 2019·Pharmaceutics·Okhil K Nag, James B Delehanty
Jan 1, 2020·Pharmaceutics·Ana Paula Dinis Ano BomSotiris Missailidis
Dec 4, 2020·International Journal of Molecular Sciences·Zhaoying Fu, Jim Xiang
Jan 5, 2021·Journal of Materials Chemistry. B, Materials for Biology and Medicine·Bruna G CarvalhoLucimara G de la Torre
Dec 2, 2020·Materials Science & Engineering. C, Materials for Biological Applications·Zahra Ranjbar-NavaziSoodabeh Davaran
Dec 29, 2020·Frontiers in Pharmacology·Jinfeng ShiChaomei Fu
Dec 16, 2020·Journal of Controlled Release : Official Journal of the Controlled Release Society·Yong Il ParkRuda Lee
Nov 15, 2020·Journal of Controlled Release : Official Journal of the Controlled Release Society·Hanieh MousazadehNosratollah Zarghami
Dec 20, 2020·Colloids and Surfaces. B, Biointerfaces·Lianjiang Tan, Changyu He
Mar 18, 2021·Journal of Liposome Research·Hanieh AbbasiSomayeh Handali
May 1, 2021·Pharmaceuticals·Frank H T NelissenHans A Heus
Jul 23, 2021·International Journal of Pharmaceutics·Alexandro AzevedoHenrique Faneca
Oct 16, 2020·European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Für Pharmazeutische Verfahrenstechnik E.V·Phuoc Vinh NguyenEmilie Allard-Vannier
Nov 18, 2020·Current Pharmaceutical Design·Shivani Rai PaliwalRishi Paliwal
Aug 28, 2021·International Journal of Molecular Sciences·Sofía Mirón-BarrosoSonia Trigueros
Feb 3, 2022·Therapeutic Delivery·Mohammed M Mehanna, Kawthar K Abla

❮ Previous
Next ❯

Methods Mentioned

BETA
exponential enrichment
electrophoresis
flow cytometry
transfection
fluorescence
xenografts
fluorescence imaging
PCR
dynamic light scattering

Software Mentioned

Prism
CellQuest
Leica
GraphPad
IMT i - Solution

Related Concepts

Related Feeds

Breast Cancer Triple-N

Breast cancer cells have receptors for estrogen, progesterone, HER2 receptors (also called ERBB2). Triple-negative breast cancers do not have any of these receptors. Here are the latest discoveries pertaining to triple-negative breast cancers.

Cancer Vaccines

Cancer vaccines are vaccines that either treat existing cancer or prevent development of a cancer.